Separately, ValuEngine lowered CryoPort from a strong-buy rating to a buy rating in a report on Tuesday, January 15th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $19.75.
Shares of CryoPort stock traded down $1.02 on Wednesday, reaching $16.72. 174,873 shares of the company were exchanged, compared to its average volume of 219,419. CryoPort has a one year low of $8.28 and a one year high of $18.99. The company has a quick ratio of 11.52, a current ratio of 11.57 and a debt-to-equity ratio of 0.42. The stock has a market cap of $512.90 million, a P/E ratio of -53.94 and a beta of 1.10.
In other CryoPort news, Director Richard J. Berman sold 30,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $11.84, for a total value of $355,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.00% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of CryoPort by 5.0% during the fourth quarter. Geode Capital Management LLC now owns 302,544 shares of the consumer goods maker’s stock valued at $3,337,000 after buying an additional 14,530 shares during the last quarter. Pier Capital LLC raised its stake in shares of CryoPort by 48.6% in the first quarter. Pier Capital LLC now owns 505,334 shares of the consumer goods maker’s stock valued at $6,529,000 after buying an additional 165,229 shares during the period. Perkins Capital Management Inc. raised its stake in shares of CryoPort by 17.4% during the 1st quarter. Perkins Capital Management Inc. now owns 173,650 shares of the consumer goods maker’s stock valued at $2,244,000 after purchasing an additional 25,750 shares during the period. Monarch Partners Asset Management LLC raised its stake in shares of CryoPort by 19.3% during the 4th quarter. Monarch Partners Asset Management LLC now owns 58,703 shares of the consumer goods maker’s stock valued at $647,000 after purchasing an additional 9,493 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of CryoPort by 50.1% during the 4th quarter. Rhumbline Advisers now owns 33,919 shares of the consumer goods maker’s stock valued at $374,000 after purchasing an additional 11,321 shares during the period. Institutional investors own 53.28% of the company’s stock.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.